Introduction: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has transformed the treatment of non-small cell lung cancer (NSCLC), yet acquired resistance remains a major challenge to its clinical efficacy. ... ...

请注册登录后继续浏览